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Available online 25 February 2010Background: Patients with depression often experience pain. There is limited understanding of
the relation between pain and other symptoms (depressive, anxious and non-painful somatic
symptoms). This exploratory study assesses pain severity and interference of pain with
functioning in a clinically depressed population and investigates the relation between the
different groups of symptoms.
Methods: FINDER was a 6-month prospective, observational study investigating health-related
quality of life of outpatients with depression initiating antidepressant treatment. Patients
completed ratings on the Hospital Anxiety and Depression Scale (HADS), Somatic Symptom
Inventory (SSI-28), and overall pain severity and interference of pain with functioning using
Visual Analogue Scales (VAS) at baseline and at 3 and 6 months. Regression analyses identified
factors associated with overall pain severity and interference of pain with functioning, at
baseline and over the observation period.
Results: Of3468eligiblepatients at baseline, 56.3% experiencedmoderate to severepain and53.6%
had moderate to severe pain-related interference with functioning. At 6 months of follow-up,
these proportions decreased to 32.5% and 28.1%, respectively. Higher baseline SSI-somatic scores
(non-painful) were strongly associated with greater pain severity and greater pain-related
interference with functioning at baseline and over 6 months. Certain socio-demographic
(increasing age, being unemployed) and depression-related factors (more previous episodes,
longer duration of current episode) were also significantly associated with greater pain severity
and interference over 6 months, while higher baseline severity of depression (HADS-D) and
further education were associated with less severe pain or pain-related interference with
functioning over 6 months.
Conclusions: Over half of depressed patients in this study experienced moderate to severe pain.
Painful somatic symptoms appear to be closely related to non-painful somatic symptoms, more
than to depressive or anxious symptoms suggesting that painful and non-painful somatic
symptoms can be considered as one group of ‘somatic symptoms,’ all of them associated with
depressive and anxious symptoms.
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Epidemiological studies show that theprevalence of chronic
painful physical symptoms is increased in patients with mood
disorders and in patients with anxiety disorders, suggesting
they are not specific to depressive disorders (Ohayon and
Schatzberg, 2003; Demyttenaere et al., 2006, 2008). The
question whether these painful physical symptoms are also
associated with the non-painful physical symptoms found in
depressed patients is not fully understood.
Co-morbid chronic painful (and non-painful) physical symp-
toms result in poorer recognition of depression (Kirmayer et al.,
1993) and in poorer outcomes of depression (Ohayon and
Schatzberg, 2003), and this may be due to several factors,
including lower rates of help-seeking and longer delays
before help-seeking when pain accompanies depression
(Demyttenaere et al., 2006), or lower efficacy of antidepressant
treatment on painful physical symptoms. Indeed, the effect size
measured after 9 months of treatment with antidepressants has
been shown to be lower for painful (and non-painful) physical
symptoms than for non somatic depressive symptoms and for
positive well-being (Greco et al., 2004). During antidepressant
treatment, remitters and non-remitted responders had signifi-
cantly more change than non-responders in both pain and non-
pain physical symptoms suggesting that the changes in the latter
two groups of symptoms occurs in parallel (Greco et al., 2004).
Moreover, the somatic symptomsbeingpart of or associated
with depression are not only influencing the outcome of
depression. Indeed, several recently published papers even
suggest that (in patients with myocardial infarction or with
chronic heart failure) the so-called somatic/affective symptoms
of depression are more predictive of overall mortality than the
cognitive/affective symptoms of depression (De Jonge et al.,
2006; Schiffer et al., 2009).
Although the recent literature focused on the ‘comorbid-
ity’ of depression and anxiety and of depression (and anxiety)
and painful physical symptoms, the relation between these
different symptom clusters (including the non-painful phys-
ical symptoms) is not fully understood. The specificity of the
comorbidity between somatoform clusters and other mental
disorders should indeed be further clarified (Lieb et al., 2007).
Pain, like many other somatic symptoms, is always a
subjective experience (from sensory to affective to cognitive
to behavioural aspects); therefore, it is important to investigate
not only pain severity and changes in pain severity but also
interference of pain with functioning and changes in pain
interferencewith functioningwhenpresentedwithdepression.
Factors InfluencingDepression Endpoints Research (FINDER)
is a multinational, longitudinal, observational study designed to
increase understanding of the factors that influence health-
related quality of life outcomes for clinically depressed out-
patients receiving antidepressant (AD) medication in routine
primary and secondary care. In this study, pain as well as its
impact on functioning and factors associated with pain was
assessed using patient-reported measures.
The aims of the present exploratory analyses were to
examine the severity of overall pain and the interference of
pain with ability to undertake normal activities both at baseline
(untreated) and over the 6-month observation period in
clinically depressed outpatients. We also investigated the
relation between pain severity and interference of pain withfunctioning with other symptom clusters (non-painful somatic
symptoms, anxious and depressive symptoms) and socio-
demographic and clinical variables at baseline and over
6 months.2. Methods
2.1. Study design
FINDER was a 6-month, observational, multi-centre,
multinational study conducted in 12 European countries:
Austria, Belgium, France, Germany, Ireland, Italy, the Nether-
lands, Norway, Portugal, Sweden, Switzerland and the UK.
Recruitment commenced in May 2004 and was completed in
September 2005. The study had a non-interventional design
which means that all treatment decisions were at the
discretion of the participating physician. The study was
approved in all countries according to local requirements
for ethics and/or regulatory approvals for observational
studies. Patients gave written informed consent for the
provision and collection of data regarding care and outcomes
during the observation period. The study design and baseline
characteristics of the FINDER study population have been
described in detail elsewhere (Garcia-Cebrian et al., 2008;
Bauer et al., 2008) and will be briefly described here.2.1.1. Patients
Patients were eligible for inclusion in the study if they
presented within the normal course of care and were
diagnosed by their physician as suffering from depression,
were about to start pharmacological treatment for either a
first or subsequent episode of depression (the index episode),
and were aged at least 18 years. Patients were not simulta-
neously participating in a different study that includes an
investigational drug or procedure.2.2. Data collection and assessments
Data were collected by investigators (either primary care
physicians or specialists — psychiatrists or neurologists — 437
investigators/study sites) or with patient rated scales at
baseline (the routine visit at which the patient agreed to
enter the study) and at 3 (±1 month) and 6 months
(±1 month) post-baseline during visits that were part of the
routine clinical care of the patient. At baseline, data were
collected on patient socio-demographics and psychiatric
history. Investigators recorded whether patients had any of a
selection of co-morbid chronic medical or functional condi-
tions. At baseline, data on healthcare resource utilisation,
psychotherapy andmedication taken (antidepressants, analge-
sics and pain-related medication, both over-the-counter and
prescribed) were collected. Antidepressants taken from base-
line were at the choice of the investigator and were grouped
into: selective serotonin reuptake inhibitors (SSRIs); tricyclic
antidepressants (TCAs); serotonin norepinephrine reuptake
inhibitors (SNRIs); others (including monoamine oxidase
inhibitors [MAOIs]); and combinations (of SSRIs, TCAs, SNRIs,
MAOIs and others).
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Pain was assessed using Visual Analogue Scales (VAS) for
overall pain severity and for interferenceof painwith the ability
to perform daily activities during the past week (i.e., function-
ing). The VAS scale ranged from ‘no pain’ (0) to ‘as severe as
imaginable’ (100). Moderate to severe pain was defined as a
score N30mmon the overall pain VAS (Collins et al., 1997). The
corresponding anchors for the interference VASwere ‘not at all’
to ‘complete disability.’ Moderate to severe interference was
determined to be present if the score was higher than 30.
TheHospital Anxiety andDepressionScale (HADS) (Zigmond
and Snaith, 1983) was completed at baseline and at 3 and
6 months as a measure of severity. The HADS consists of seven
items for depression (HADS-D) and seven items for anxiety
(HADS-A), assessing how the patient felt during the past week.
Each item is scored on a 4-point scale from 0 to 3, leading to
subscale scores for HADS-D and HADS-A of between 0 and 21.
Somatic symptoms (including both painful and non-painful
items) were measured using the 28-item Somatic Symptom
Inventory (SSI-28), where each item was rated according to
howmuch it bothered the patient over theprecedingweek on a
scale from 1 (not at all) to 5 (a great deal) (Barsky et al., 1986).
The pain subscore (SSI-pain) was derived by calculating the
average score over 7 pain-related items, and the somatic
subscore (SSI-somatic) used the remaining 21 items.
2.4. Analysis
Two pain groups were defined using the overall pain VAS
rating: (1) ≤30 mmwas defined as having no/mild pain; and
(2) N30 mm was defined as having moderate to severe pain
(Collins et al., 1997). Descriptive summary statistics (means,
standard deviations [SDs], frequencies, percentages) were
used to describe the patients in the two pain groups.
Multivariate linear regression analysis was performed to
identify variables independently associatedwith (a) severity of
overall pain (overall pain VAS) at baseline, and (b) interference
of pain with ability to perform normal activities (pain
interference VAS) at baseline. The independent variables
included in the regression analyses were: continuous baseline
variables: HADS-A, HADS-D, overall pain VAS [for analysis of
interference of pain only], SSI-somatic score, age, body mass
index (BMI), number of dependants (the number of depen-
dents that the patient has, including those living with the
patient, e.g. children of elderly relatives, and those whomay be
living away from home but are still dependents, such as
students), duration of current depressive episode, age at first
depressive episode, number of previous episodes of depression
in the 24 months before baseline; categorical variables: gender,
marital status (married/domestic partner, other), education
(none/mandatory, further), occupational status (working for
pay, unemployed, other), smoking (yes, no), medical condi-
tions (known to be painful, non-painful, none: recorded from a
pre-specified list of two groups of disorders: (1) a defined co-
morbid physical condition known to cause pain— the presence
of angina, malignant disease (cancer), neuropathic disorder,
rheumatological disorder and/or (2) who indicated yes to
suffering any physical trauma in the last 24 months fromwhich
pain effects still exist, termed ‘painful medical condition,’ a
defined co-morbid physical condition not associated with pain(by not confirming the presence of any of t he conditions listed
for the explained pain group; diabetes, hypertension, asthma
were considered non-painful conditions) termed ‘non-painful
medical condition’ and (3) no medical condition), functional
conditions (collected froma pre-specified list including chronic
fatigue, irritable bowel syndrome, atypical chest pain, irritable
bladder, fibromyalgia and chronic pelvic pain), any psychiatric
illness in the 24 months before baseline (yes, no) and country.
The full models containing all of these variables were reduced
by backward elimination methods to include only those
independent variables that were statistically significantly
associated with the outcome variable at p≤0.05.
Similarly, repeated measures regression analyses were
performed for the two dependent variables over 6 months,
including the same independent variables as above, but adding
the baseline score for the dependent variable, the group of
antidepressant taken between baseline and 3 months (combi-
nations, other drugs, SNRIs, SSRIs, TCA), the class of analgesic
taken between baseline and 3 months (no analgesic treatment,
simple, NSAIDs, opioids), and the overall pain VAS at baseline
(for analysis of pain interference only). Independent variables
are sorted in order of the strength of the association with the
outcome in each case (based on the p-values). Due to the
exploratory nature of the analysis there were no adjustments
made for multiple comparisons.
2.4.1. Analysis of loss to follow-up
Weperformedananalysis todeterminewhetherpatients lost
to follow-up after 3 months differed systematically in their initial
pain response (i.e. the change between baseline and 3 months in
pain severity) from patients who had assessments at the end of
6 months. For this purpose, we compared the baseline char-
acteristics and change scores from baseline to 3 months for
overall pain severity for two groups of patients: Group 1 =
patients with data at 3 months only; and Group 2 = patients
with data at both 3 and 6 months (i.e. at all visits) or at 6 months
only. This analysis is further supported by the results of a logistic
regression analysis performed to identify those variables
significantly associated with loss to follow-up.
All analyses were conducted using SAS version 8.2.
3. Results
There were 3468 patients with a clinical diagnosis of
depression in the study, of whom, 3308 had a non-missing
overall pain rating at baseline and were, thus, eligible for
inclusion in the current analysis. Of these patients, 1861 (56.3%)
had moderate to severe pain (based on overall pain VAS
N30 mm) at baseline, and 1447 (43.7%) had no/mild pain. Of
the 1861 patients with moderate to severe pain, 1311 (70.4%)
had no recorded physical explanation for the pain. Table 1
summarises the baseline characteristics of the patients with and
without moderate to severe pain at baseline. There were some
differences between pain groups in socio-demographics, but few
differences in psychiatric history. There were more comorbid
chronic medical and functional conditions and higher baseline
scores of depression and anxiety (HADS) among patients with
moderate/severe pain compared to those with no/mild pain.
Fig. 1 presents the VAS frequency distribution at baseline
and at6 monthsof (a) overall pain severity and (b) interference
of pain with ability to perform daily activities (i.e. functioning).
Table 1





Female, % 66.0 69.8
Age, years 44.8 (14.5) 48.3 (14.7)
Further education, % 53.8 43.4
Paid employment, % 56.6 45.2
BMI, kg/m2 24.8 (4.8) 26.0 (5.5)
Duration of current depressive episode,
weeks
13.6 (16.2) 13.7 (17.0)
Duration of depression, years 8.0 (10.1) 8.9 (10.6)
Anypsychiatric illness in last 24 months, % 52.3 58.0
Any current chronic medical condition, % 31.2 51.1
Painful 13.1 29.9
Non-painful 20.9 25.1
Any current chronic medical condition, % 31.2 51.1
Any current functional syndrome, % 30.4 47.6
HADS depression score (0–21) 11.6 (4.6) 12.9 (4.3)
HADS anxiety score (0–21) 12.2 (4.1) 13.6 (3.8)
Overall pain VAS (0–100) 11.6 (10.4) 61.4 (17.5)
Pain interference with functioning VAS
(0–100)
16.0 (20.8) 57.2 (26.5)
SSI-28 1.9 (0.5) 2.6 (0.7)
SSI-pain 1.8 (0.6) 2.8 (0.8)
SSI-somatic 1.9 (0.6) 2.5 (0.7)
Data presented as mean (SD) unless indicated otherwise.
No/mildpain=anoverall painVAS ratingof≤30 mm,moderate/severepain=
an overall pain VAS N30 mm.
BMI, body mass index; HADS, Hospital Anxiety and Depression Scale; SSI,
Somatic Symptom Inventory; VAS, visual analogue scale.
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severe pain. In addition, 53.6% of patients had moderate to
severe interference of pain with functioning (VAS N30 mm). At
6 months, VASpain ratingswere available for 2700patients and
the frequency distribution figure shows that the proportion of
patients with moderate to severe pain and interference of pain
with functioning had fallen to 32.5% and 28.1%, respectively.
There was a relationship between overall pain and
interference of pain with functioning such that of the 1861
patients with moderate to severe pain at baseline, 81.7% also
demonstrated interference of this pain with daily activities.
Likewise, of the 1447 patients without moderate to severe
overall pain at baseline, only 17.6% had significant pain
interference with functioning. This relationship endured over
the observation period, with 74.1% of those patients with
moderate to severe pain over 6 months reporting significant
interference of pain with functioning.
3.1. Factors associated with pain at baseline
Table 2 summarises the independent variables signifi-
cantly associated with overall pain severity at baseline. A
higher SSI-somatic score, any presence of concurrent medical
conditions, and a higher BMI were associated with greater
pain severity at baseline, while having further education was
associated with lower pain severity (Table 2).
The independent variables significantly associated with
greater interference of pain with functioning at baseline
(Table 2) were greater severity of overall pain, higher SSI-
somatic score, higher HADS depression score, higher BMI, and
occupational status (not working for pay). Having furthereducation, increasing age and being female were associated
with less interference of pain with functioning at baseline.
3.2. Factors associated with pain over 6 months
The following independent variables were significantly
associated with greater overall pain severity over 6 months
(Table 3): greater overall pain severity at baseline, higher SSI-
somatic score at baseline, taking analgesics (especially
opioids) between baseline and 3 months, any presence of
concurrent medical condition, increasing age, longer duration
of the current episode of depression, greater number of
previous episodes of depression and being unemployed. More
severe depression at baseline (i.e. a higher HADS-D score) and
a higher educational level were associated with lower overall
pain severity over the 6-month observation period.
Table 4 summarises the independent variables signifi-
cantly associated with interference of pain with functioning
over 6 months. Positive associations (i.e. associations with
greater interference of pain) were observed for taking
analgesics (especially opioids) between baseline and
3 months, a higher baseline SSI-somatic score, greater overall
pain severity and interference of pain at baseline, longer
duration of the current episode of depression, presence of a
painful medical condition, greater age, a higher number of
previous episodes of depression, being unemployed, and a
greater BMI. Having further education, more severe depres-
sion at baseline (a higher HADS-D score) and being married
or having a partner were associated with less pain interfer-
ence with functioning over 6 months.
Individual groups of ADs taken between baseline and
3 months were not significant compared to no treatment over
6 months for either pain severity or interference of pain with
functioning although AD group was retained in each model
because there were significant differences between other
pairs of AD groups. In general, those taking a combination of
AD treatments had worse pain severity and interference of
pain over 6 months than the other AD groups.
3.3. Loss to follow-up analysis
Of the 3468 patients at baseline, 343 (9.9%) had no follow-
up data, 271 (7.8%) had data at 3 months only (Group 1, see
Methods section), and 2854 (82.3%) had data at both 3 and
6 months (“all visits,” Group 2) or 6 months only (Group 2,
see Methods section).
Examination of the changes in overall pain ratings during
the first 3 months of treatment in Group 1 and Group 2
revealed no systematic differences (data not shown).
The logistic regression model comparing the patients lost
to follow-up after 3 months with those who had 6-month
data identified three variables that were significantly associ-
ated with loss to follow-up: country (pb0.001), younger age
at first depressive episode (p=0.001) and higher SSI-somatic
score at baseline (p=0.019). Overall pain severity was not
retained in the model and, therefore, was not significantly
associated with the likelihood of remaining in the study. This
provides some evidence that the results on the pain outcomes
will not be systematically biased due to missing information
on the patients lost to follow-up.
Fig. 1. VAS frequency distribution of overall pain severity and interference of pain with ability to perform daily activities at baseline and at 6 months.
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A first important finding of this naturalistic study is the
presence of pain in a high proportion of patients in this
population of help-seeking patients with clinically diagnosed
depression. Indeed, more than half of the patients had
moderate to severe pain (during the past week), which is
consistent with previously published data on the relation
between depression and more chronic pain (Ohayon and
Schatzberg, 2003; Bair et al., 2003, 2004; Demyttenaere et al.,
2006). One-third of the patients continued to report moderate
to severe pain at the end of the observation period. The severityof pain was reflected in the high likelihood of pain interfering
with daily activities both at baseline (in 81.7% of patients with
pain) and over 6 months of follow-up (in 74.1% of patientswith
pain).
An second important finding of this study is the close
relationship between painful symptoms and non-painful somat-
ic symptoms, as assessed with the Somatic Symptom Inventory
which asked howmuch individual symptoms botheredpatients:
e.g. nausea or vomiting, feeling faint or dizzy, troublewith vision.
A higher score for somatic symptoms was one of the strongest
predictors of higher overall pain at baseline as well as over
6 months, and suggests that these groups of symptoms are
Table 2
Linear regression: independent baseline variables significantly associated with severity of overall pain (overall pain VAS) and interference of pain with ability to
perform daily activities (pain interference VAS) at baseline.
Independent variable Estimate F value p value
Severity of overall pain (n=3062) SSI-somatic score 18.8 893 b0.001
Medical conditions (reference: none) 56 b0.001
Painful 12.1
Non-painful 4.9
Further education (reference: none/mandatory) −3.3 11 b0.001
BMI 0.3 11 b0.001
Country (reference: UK) – 4 b0.001
Pain interference (n=3013) Severity of overall pain 0.7 2114 b0.001
SSI-somatic score 7.0 113 b0.001
HADS depression score 0.5 32 b0.001
Further education (reference: none/mandatory) −2.0 5 0.021
BMI 0.2 5 0.024
Age −0.1 4 0.034
Occupational status (reference: paid work) 3 0.037
Unemployed 2.0
Other 2.1
Female sex (reference: male) −1.6 4 0.046
Independent variables are sorted in order of the strength of the association with the outcome. Country was not statistically significant (p=0.161) for pain
interference, but forced into the reduced model.
BMI = body mass index; SSI, somatic symptom inventory; HADS, hospital anxiety and depression scale.
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shown that the presence of painful symptoms compromises the
outcome of antidepressant treatment (Ohayon and Schatzberg,
2003; Bair et al., 2003, 2004), the present findings suggest thatTable 3
Linear regression: independent baseline a variables significantly associated
with overall pain severity (VAS) over 6 months (n=2436).
Independent variable Estimate F value p value
Severity of overall pain (VAS) 0.4 489 b0.001
SSI-somatic score 5.4 64 b0.001
Class of analgesic a





HADS-D −0.5 29 b0.001
Medical conditions (reference: none) 15 b0.001
Painful 5.5
Non-painful 3.7
Age 0.1 13 b0.001
Duration of current depressive episode 0.1 11 b0.001




Occupational status (reference: paid work) 5 0.007
Unemployed 3.7
Other ns
AD group a (reference: no treatment) – 2 0.043
Country (reference: UK) – 4 b0.001
Independent variables are sorted in order of the strength of the association
with the outcome.
Note: individual classes of AD taken between baseline and 3 months were not
significant compared to no treatment, but the term was retained in the model
because there were significant differences between other pairs of AD groups:
combinations and SSRI (adjustedmeans 34.8 and 31.6, respectively; p=0.010),
combinations and other drugs (34.8 and 31.0; p=0.037).
AD, antidepressant; HADS-D,Hospital Anxiety andDepression Scale depression
score; ns, not significant; NSAIDs, non-steroidal anti-inflammatory drugs; SSI,
Somatic Symptom Inventory; VAS, visual analogue scale.
a AD and analgesic taken were those for the observation period between
baseline and month 3.non-painful physical symptoms should probably also be taken
into account as possible predictors of treatment response in
depression. A higher non-painful physical symptom score was
also one of the strongest predictors of interference of pain with
functioning at baseline and over 6 months, independent from
overall pain severity. This suggests that non-painful physical
symptoms aggravate the influence of pain on functioning, or that
patients attribute the impaired functioning to the pain severity
rather than to the severity of co-existing non-painful physical
symptoms.
It is remarkable that the association between painful physical
symptoms and non-painful physical symptoms is stronger than
between painful physical symptoms and depressive or anxious
symptoms (as assessed with the HADS). This suggests that they
probably are better understood as one group of ‘somatic’ or
‘somatoform’ symptoms instead of focusing separately on the
one (painful) or the other (non-painful) subgroup. Standard
rating scales for somatic symptoms (like the SSI, the Patient
Health Questionnaire-somatization subscore or the Symptom
Check List-somatization subscore) indeed cluster them into one
group of symptoms. One could suggest to cluster the broad
symptom presentation of many patients into ‘depressive,’
‘anxious’ and ‘somatoform’ (painful and non-painful) symptom
clusters. This supports the recent proposal that ‘a potential
consideration for future diagnostic classification would be to
describebasicdiagnostic criteria for a singleoverarchingdisorder
(general neurotic syndrome or negative affect syndrome) and to
optionally code additional diagnostic features that allow a more
detailed classification into specific depressive, anxious and
somatoform subtype’ (Löwe et al., 2008).
The presence of a painful medical condition is a logical
predictor of pain at baseline as well as over 6 months. Although
treatment with antidepressants may be effective in reducing
some forms of pain (e.g. those linked to depression or
neuropathy) independent of amood-enhancing effect (Dworkin
et al., 2007; McCleane, 2008), the additional use of opioids by a
subgroup of patients requiring this level of pain control in
conjunction with antidepressant treatment indicates that such
Table 4
Linear regression: independent baseline a variables significantly associated
with interference of pain with ability to perform daily activities over
6 months (n=2303).
Independent variable Estimate F value p value
Interference of pain 0.2 133 b0.0001
Class of analgesic a





SSI-somatic score 5.2 50 b0.0001
Severity of overall pain (VAS) 0.1 21 b0.0001
Further education (ref: none/mandatory) −3.1 12 b0.001
Duration of current depressive episode 0.1 11 b0.001
Medical conditions (ref: none) 6 0.002
Painful 4.1
Non-painful ns
Age 0.1 9 0.002
HADS-D −0.3 9 0.003
Number of previous episodes of depression 0.9 9 0.003
Occupational status (ref: paid work) 3 0.038
Unemployed 3.1
Other ns
BMI 0.2 4 0.039
Marital status (ref: other)
Married/domestic partner −1.7 4 0.043
AD group a (ref: no treatment) – 6 b0.001
Country (ref: UK) – 2 0.006
Independent variables are sorted in order of the strength of the association
with the outcome.
Note: AD group taken between baseline and 3 months was not significant
compared to no treatment, but was retained in themodel because there were
significant differences between other pairs of AD groups: combinations and
SSRIs (adjusted means 33.6 and 26.8, respectively; pb0.001); combinations
and SNRIs (33.6 and 29.8; p=0.028); combinations and TCAs (33.6 and 29.6;
p=0.036), SNRIs and SSRIs (29.8 and 26.8; p=0.024).
AD, antidepressant; BMI, body mass index; HADS-D, Hospital Anxiety and
Depression Scale depression score; ns, not significant; NSAIDs, non-steroidal
anti-inflammatory drugs; SSI, Somatic Symptom Inventory; VAS, visual
analogue scale.
a AD and analgesic taken were those for the observation period between
baseline and month 3.
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that the presence of a non-painful medical condition is also
significantly associatedwith overall pain severity at baseline and
during 6 months of AD treatment is interesting. We hypothesise
that this could be due to the fact that patients do not make a
distinction between the importance of painful versus non-
painful symptoms when they are asked to assess the severity of
pain, i.e. they take into account the somatic sensations of
symptoms when evaluating pain.
Several socio-demographic characteristics (gender, age,
BMI, educational level, occupational status) were associated
with pain and related interference with functioning in this
sample of clinically depressed outpatients, both at baseline
and over the 6-month follow-up period. At baseline,
increasing age and female gender were significantly associ-
ated with less pain-related interference with functioning but
not with overall pain severity. However, increasing age was
significantly associated with higher pain scores and greater
interference with functioning over 6 months. These latter
findings are consistent with previous studies that older age is
associated with increased pain severity (Bair et al., 2004;
Demyttenaere et al., 2006).A higher education level was consistently associated with
lower pain severity and lower interference of pain with
functioning at both baseline and during the observation period.
These confirm previous findings of an inverse relationship
betweeneducational attainment and pain (Demyttenaere et al.,
2006).
There are high rates of unemployment and impairments in
social functioning among patients with depression and pain
(Bair et al., 2003). In the present study, patients not in paid
work had greater pain-related interference with functioning at
baseline and over 6 months of treatment than patients in paid
work. Unemployed patients also had greater pain severity over
the 6-month follow-up period than patients in paid work. This
suggests that reporting of pain and interference of pain with
functioning is also moderated by socio-demographic variables
again underlining the ‘subjective experience’ of pain.
When comparing the mean baseline depression severity
scores (HADS)between thepatientswithno/mildpainand those
withmoderate to severe pain, it appears that patientswithmore
pain have higher depression severity. This relationship is not
statistically significant in themultivariatemodel onbaselinepain
severity but it is significant in the model on baseline pain
interference. In other words, severity of baseline depression is
not significantly associatedwith severity of pain at baseline once
all other variables are taken into account although it is positively
associated with pain interference at this time.
For the 6-month outcomes, there was a somewhat counter-
intuitive result that higher depression severity at baseline
predicts lower pain severity over the observation period. It has
been documented that the reporting of pain severity is partly
determined by depression severity (Shelton et al., 2007).
Therefore, patients with a higher baseline depression severity
could have lowerpain severity at endpoint because a largerpart
of the baseline pain intensity was depression severity-associ-
ated. In this analysis, we have not investigated the change in
HADS-D scores as a time-dependent variable in the models to
investigate this further.
Two depression-related factors were significantly associat-
ed with greater pain severity and pain-related interference of
functioning over 6 months: a longer duration of the current
depressive episode and a higher number of previous depressive
episodes, whereas age at first depressive episode was not
maintained in the models. Previous studies report that the
duration of depressive episodes is longer in patients with pain
than in thosewithout pain (Ohayon and Schatzberg, 2003), and
that patientswith co-existingdepression andpain tend todelay
seeking help (Demyttenaere et al., 2006).
Combinations of AD treatments were associated with poorer
pain outcomes over 6 months butmay represent a patient group
who are harder to treat.
The loss to follow-up analysis showed that patients
discontinuing from the study between months 3 and 6
responded similarly during the first 3 months of observation
comparedwith patients who completed the study, suggesting
that these losses did not result in systematic under- or
overestimates of changes in pain ratings over time.
This study has several limitations that affect the interpre-
tation and generalisability of the results.
First, the pain measures are limited to ‘overall pain sever-
ity during the past week’ and to ‘interference of pain with
functioning during the pastweek.’ The pain experience is known
60 K. Demyttenaere et al. / Journal of Affective Disorders 125 (2010) 53–60to be complex and more detailed information on duration of
pain, and on location of pain symptoms could have had added
value. Anyhow, the ‘complete pain experience’ can never be fully
captured with questionnaires.
Second, several variables (length of episode, previous
episodes of depression, somatic comorbidity, ...) were
gathered via medical records, patient report and clinical
interview rather than form standardized diagnostic inter-
views. However, the most important variables (depressive,
anxious, non-painful and painful physical symptoms) were
all gathered with standard and well validated questionnaires
and all covered the same duration (past week).
Third, the observation period was limited to 6 months,
during which approximately one-third of patients reported
enduring moderate to severe pain. Thus, a longer follow-up
period may have identified the presence of a specific patient
subgroup with ‘refractory’ pain and depression.
Fourth, analagous to the well-documented 30mm cut-off
threshold on the VAS to define moderate to severe pain, we
used this value also to determine interference with functioning
due to pain. Although not previously reported in the literature
as a significant cut-off for this measure, it does have some face
validity, and was used only descriptively in this analysis.
In conclusion, this longitudinal exploratory study has shown
the presence of moderate/severe pain and pain-related interfer-
ence with functioning among more than half of clinically
depressed outpatients, which persisted in about one-third of
patients after 6 months. A higher score for non-painful somatic
symptoms at baseline was consistently strongly associated with
greater pain severity and pain-related interference with func-
tioning over 6 months suggesting their close association. These
findings potentially add to the discussion on future diagnostic
classification of (non-painful and painful) somatic symptoms in
patients with mood or anxiety disorders. Certain socio-demo-
graphic factors (increasing age, being unemployed) and depres-
sion-related variables (more previous episodes, longer duration
of current episode) were also significantly associated with
greater pain severity and interference with functioning, while a
higher score for depression (HADS-D) and further education
were associated with less severe pain or pain-related interfer-
ence with functioning over 6 months.
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